2024 Poster Presentations

POSTER SESSION A: Tuesday - Wednesday morning

A01: Enhancing Preclinical Toxicity Predictions: Leveraging Generative Models in Drug Development, Presented by Shuaib M., AbbVie

A02: Regulatory T Cell Interaction Within the Tumor Microenvironment: Targeting CCR8 for Enhanced Cancer Immunotherapy, Presented by Nari K., Asan Institute for Life Sciences

A03: A Proven Activity-Based Workflow for the Identification and Characterization of Time-Dependent Kinase Inhibitors Using a Continuous Assay Format, Presented by Earl M., AssayQuant Technologies, Inc.

A04: The Development and Application of a HiTChem Platform for Multiplexed Targeted Detection Using Fully Functionalized Photofragments, Presented by Yuanyuan S., AstraZeneca Pharmaceuticals

A05: A Novel Pan-RAS Inhibitor, ADT-1004, with Efficacy and Tolerability Advantages Over Other RAS Inhibitors to Suppress Tumor Growth in Multiple Mouse Models of Pancreatic Cancer, Presented by Gary P., Auburn University

A06: A Novel RAS/β-Catenin Inhibitor, ADT-030, Induces Tumor Regression and Inhibits Metastasis with “Cures” in Multiple Mouse Cancer Models, Presented by Gary P., Auburn University

A07: Zero-Shot Multi-Objective Antibody Evolution Using Multi-Agents, Presented by Wei L., Aureka Biotechnologies

A08: Rapid Engineering of GPCR Targeting Antibodies by Autonomous Hypermutation in Yeast, Presented by Alon W., Aureka Biotechnologies

A09: Discovery and Characterisation of a Novel TRPML1 Agonist, Presented by Angelo P., BioAscent Discovery Ltd.

A10: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Haoming Z., Biointron Biological USA, Inc.

A11: From Fragments, to Molecules to Approved Drugs: Easy Screening and Med Chem Support with the Carterra ULTRA HT-SPR and CarnaBio’s Biotinylated Kinome, Presented by Adam S., CarnaBio USA, Inc.

A12: The Development of a Novel Mobility Shift Analysis System for Kinase Small Molecule Drug Discovery Using the SCIEX BioPhase 8800, Presented by Adam S., CarnaBio USA, Inc.

A13: Selectivity and Cooperativity of PROTAC®s Using HT-SPR, Presented by Maria M., Carterra, Inc.

A14: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Maria M., Carterra, Inc.

A15: DELivering Mechanism of Inhibition Studies to Characterize Mutant Selective Kinase Inhibitors, Presented by Katherine J., Charles River Laboratories

A16: Structure-Based Charge Calculations for Predicting Properties and Profiling Antibody Therapeutics, Presented by Alain A., Chemical Computing Group

A17: Exploring the Dynamic Changes of Nucleic Acids to Evaluate the Effect of Protonated Nucleotides on Structure and Binding, Presented by Philippe A., Chemical Computing Group

A18: Discovering Ligands Targeting the Conserved RNA Binding Site of SARS CoV 2 NSP13 Using V-Synthes Approach: Cache Challenge 2, Presented by Olga T., Chemspace LLC

A19: Validation of a New Methodology to Create Orally Available Cyclic Peptides for Intracellular Tough Targets, Presented by Yugo K., Chugai Pharmaceutical Co., Ltd.

A20: New Modalities for 3D Virtual Screening of Ultra-Large Chemical Spaces, Presented by Sylvie S., Cresset

A21: Next Generation Copolymers for the Characterization of Membrane Proteins in Near-Native Conditions, Presented by Barbara M., Cube Biotech

A22: Domainex Hit ID Platform – Accelerated Workflow by a Partial PROTAC® Library and a Direct-to-Biology Approach, Presented by Ray B., Domainex Ltd.

A23: LC-MS Based Covalent Fragment Screening Strategy, Presented by Ray B., Domainex Ltd.

A24: Fragment Screening of Adenosine A2a Receptor Using Native Lipid Nanodiscs, Presented by Philip R., Domainex Ltd.

A25: Integral Membrane Proteins for Biophysics and Cryo-EM Applications – Case Study of the Ion Channel TrpML3, Presented by Philip R., Domainex Ltd.

A26: Affinity Selection Mass Spectrometry in Hit-Identification for Difficult-to-Drug Targets, Presented by Jean-Yves O., Edelris SAS

A27: Dual Applications of the SPRINTer Platform: Target Engagement and Targeted Protein Degradation Assay from Degrader Discovery to Functional Assay, Presented by Daniel B., Eurofins DiscoverX

A28: Comprehensive Helicase Solutions: Protein Production, Biochemical, Biophysical Assays, Selectivity Panel & Safety Assessment, Presented by Jean B., Eurofins Discovery

A29: LeadHunter STAT SH2 Binding Assays Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease, Presented by Jean B., Eurofins Discovery

A30: AI/ML-Ab (Aim-Lab) AI Assisted De-Novo Design and Discovery, Presented by Richard B., Fusion Antibodies plc

A31: Mammalian Display for Antibody Discovery, Presented by Richard M., Fusion Antibodies plc

A32: Comparative Evaluation of Cell-Based Assay Technologies for Scoring Drug-Induced Condensation of SARS-CoV-2 Nucleocapsid Protein, Presented by Rui Tong Q., Harvard Medical School

A33: Offering a Hyper-Organized Library of Microbial Dark Matter Chemistry to Pharma Companies, Presented by Peter S., Helmholtz Institute for Pharmaceutical Research Saarland

A34: A WRN Screening Cascade to Facilitate Novel Drug Discovery, Presented by Cong H., ICE Bioscience

A35: DDR Cell Panel For Novel Drug Discovery, Presented by Cong H., ICE Bioscience

A36: Preclinical Safety Assessment for Specificity of Biotherapeutics Using the Membrane Proteome Array, Presented by Joseph R., Integral Molecular

A37: Critical Factors of Transmission of Antibiotic Resistance in Multidrug-Resistant Pathogens, Presented by Jung Hun L. and Sang Hee L., Myongji University

A38: Identification of a Novel Receptor-Mediated Transcytosis Target for the Generation of Single-Domain Antibodies as Therapeutic Carriers Across the Blood-Brain Barrier, Presented by Kasandra B., National Research Council Canada

A39: Identification and Characterization of Small Molecules Inhibiting RNA Targets: miRNA, Presented by Paola C., NovAliX

A40: PCKD, the Most Relevant Model for ADPKD, Presented by Laurent S., NovAliX

A41: Discovery and Characterization of Kv1.3 Antibodies using OmniChicken® and Ion Channel Technology Platforms, Presented by Allison G., OmniAb

A42: Kinase Activity Profiling Identified Role of Eph/Ephrin System in Molecular Subtyping of Colorectal Carcinoma Patient Derived Xenograft Models, Presented by Gitanjali D., PamGene International B.V.

A43: Integrated Proteomics, Metabolomics, and Transcriptomics Reveals Systemic and Localized Metabolic Disruptions in Colorectal Cancer, Presented by Tiffany B., PanomeBio

A44: Unbiased Selectivity Profiling - Cellular Thermal Shift Assay (CETSA) with MS Detection, Presented by Stina L., Pelago Bioscience

A45: G-Protein Toolbox and Other Strategies for a Focused Approach to Cryo-EM GPCR Projects, Presented by Stephan K., Proteros biostructures GmbH

A46: Discovery and Characterization of Antibodies Against Challenging Membrane Protein Targets Using Salipro® Nano-Membrane Particles, Presented by Peter J., Salipro Biotech AB

A47: IL-17A and IL-23 Crystallization Systems Supporting Structure-Based Drug Design, Presented by Raymond K., SARomics Biostructures AB

A48: Discovery of First-in-Class Highly Selective Wee2 Inhibitors, Presented by Shelby E., Schroedinger, Inc.

A49V: Investigating Lymphatic Disorders, Malignancies and Naturopathic Management, Presented by David J., Sonoran University of Health Sciences

A50: The Discovery of a Novel Peptide Inhibitor Targeting Peptidoglycan-Induced Inflammation, Presented by MiYoung L., Soonchunhyang University

A51: The Discovery of an Inhibitor Against LPS and Peptidoglycan-Induced Muscle Atrophy, Presented by MiYoung L., Soonchunhyang University

A52: Discovering Better Hits: Advancing Drug Discovery Using Symeres’ SymeGold Library, Presented by Bart D., Symeres

A53: Development of a Novel MET Antibody-Drug Conjugate-Based Combination Therapy to Prevent Colorectal Cancer Plasticity and Drug Resistance, Presented by Shraddha S., University of Texas MD Anderson Cancer Center

A54: DELs in Cells: Direct Screening of DNA Encoded Libraries for PPI Inhibitors, Presented by Leif L., Vipergen Aps

A55: Discovery of Reversible Covalent Binders to Bfl-1 Using DNA-Encoded Chemical Libraries, Presented by Ying Z., X-Chem, Inc.

A56: Site Selective Screening: Using Biophysics to Define Mode of Action, Presented by Masakazu K., ZoBio BV

POSTER SESSION B: Wednesday afternoon - Thursday

B01: Discovery of Diverse GPCR-Targeted Antibodies Using Integrated Technologies, Presented by Kush D., AbCellera

B02: Discovery and Engineering of Bispecific Anti-CD3 Heavy Chain-Only Antibodies, Presented by Hannah W., Adimab LLC

B03: Mining Microorganisms for GPCR Ligands: Identification of LPA3 Agonism as a Key Modulator of Neuroinflammation by ADS024, Presented by Susan A., Adiso Therapeutics

B04: MegaR Technology Generates Stable, Ligand-Free, Pure GPCR Proteins and Structures for Drug Discovery, Presented by Poonam V., Alphelix Biotech Co., Ltd.

B05: From Text to Genes: Can LLMs Enhance Expression Annotations?, Presented by Dawid R., Ardigen

B06: Development of A THP-1 Assay Ready Product for Cell-Based Assays, Presented by Diana D., ATCC (American Type Culture Collection)

B07: Predicting GPCR Signaling Efficacy and Understanding Mechanisms with Machine Learning, Presented by David C., Biagon, Inc.

B08: Accelerating Antibody Drug Development with Fully Humanized Mice, Presented by Lei S., Biointron Biological USA, Inc.

B09: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Huanyi Y., Biointron Biological USA, Inc.

B10: Enabling Research Tools for αβ and γδ T Cell-Based Immunotherapy, Presented by Michelle K., BPS Bioscience, Inc.

B11: Fragment-Based Drug Discovery (FBDD) Approach for IRAK4, Presented by Raniya A., Cayman Chemical Company

B12: MICRO-TAG™ Cell Target Engagement Platform from Discovery to Optimization, Presented by Elmar N., CellarisBio

B13: A Novel Real-Time Cellular Target Engagement Platform for Challenging Drug Targets, Presented by Elmar N., CellarisBio

B14: Discovery of Novel CHD4 Inhibitor to Regulate Foxp3+ Treg Cells and Enhance Immunotherapy, Presented by Elmar N., CellarisBio

B15: From Raw Dose Response Curves to Pharmacodynamic Classification: An Automatic Analysis Pipeline for GPCR Ligands, Presented by Derek R., Centre de Recherche du CHU Sainte-Justine

B16: A Rapid High-Throughput and Effective Process for Identifying Molecular Glues Using Affinity Selection Mass Spectrometry (ASMS), Presented by Katherine J., Charles River Laboratories

B17: Development of a Ternary Complex Assay by SPR for PROTAC Drug Discovery, Presented by Sarah T., Charnwood Discovery

B18: Targeted Protein Degradation with Heterobifunctional Degraders: Modeling and Screening, Presented by Alain A., Chemical Computing Group

B19: Chemoproteomic Discovery and Preclinical Development of a Covalent Targeted Radioligand (CTR) Targeting Fibroblast Activation Protein (FAP), Presented by Fengying Z., ChomiX Biotech Co., Ltd.

B20: Interpretable Machine Learning Uncovers Mechanisms Of Protein-Protein Coupling, Presented by Elizaveta M., City of Hope, Beckman Research Institute

B21: Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI, Presented by Jamie S., Concept Life Sciences

B22: FragAI: Unlocking Chemical Matter Using “Crystal Structure First” Approach and Generative AI, Presented by Serghei G., CrystalsFirst GmbH

B23: Preclinical Validation of γ-Secretase Modulator GSM 776890 for Alzheimer’s Disease Prevention, Presented by Ronald B., Curia

B24: Moving the Scale for Obesity Therapeutics – From Bench to Bedside: Functional Cell-based Assays for GLP-1, GIP, & Beyond, Presented by Raghu B., Eurofins DiscoverX

B25: Hands-off Screening with Cells: Automation of a Cellular Biosensor to Facilitate Efficient Hit Compound Screening, Presented by Laura T., Exscientia Ltd.

B26: Rapid Protein Proteolysis Inducer Discobery System, RaPPIDS, Advancing Degrader Discovery by Two Different Approaches, Presented by Kazuteru A., FIMECS, Inc.

B27: Investigating Structure and Dynamics of Biologically Relevant Macromolecules Through EPR Distance Measurements, Presented by Austin GJ., High Q Technologies, Inc.

B28: Anti-Obesity Related Target Assay Development and Application, Presented by TJ B., ICE Bioscience

B29: Structural Analysis and Epitope Mapping of Membrane Proteins in Live Cells with Amino-Acid Resolution and High-Throughput, Presented by Hetal M., Immuto Scientific

B30: GLP-1R and GIPR Cell-Based Reporter Assays: New Tools to Advance the Development of Therapeutics for Type II Diabetes and Obesity, Presented by Andrew W., INDIGO Biosciences, Inc.

B31: Next Generation Gene Design Using codABLE™ Algorithm, Presented by Masha K., Ingenza Ltd.

B32: Discovery and Development of the Small Molecule Antiviral Against Pan-Coronavirus Using Phenotypic High Throughput Screening, Presented by BoRa L., Institut Pasteur Korea

B33: Causal Modelling of Sjogren’s Disease Using Swarm Based Deep Learning for Therapeutic Target Identification, Presented by Robert G., Intelligent OMICS Ltd.

B34: Discovering Novel Drugs by Targeting Ubiquitin Proteasome System for PROTACs and Molecular Glues, Presented by Karteek K., LifeSensors, Inc.

B35: Superior Luciferase Reporter System to Discover Targeted Protein Degradation Drugs, Presented by Karteek K., LifeSensors, Inc.

B36: Optimization of Ghrelin Receptor Bias Modulators for the Treatment of Addictive Disorders, Presented by Konstantinos A., National Institutes of Health, National Center for Advancing Translational Sciences

B37: Chemogenomic Screens Identify Chemical Entities for the Activation of Delta-Globin Gene Expression, Presented by Sinead C., National Institutes of Health, National Center for Advancing Translational Sciences

B38: NIH Blueprint Neurotherapeutics Network (BPN): Funding and Resources for the Discovery of Novel Drug Candidates for the Treatment of Neurological Disorders, Presented by Enrique M., National Institutes of Health, National Institute of Mental Health

B39: Integrating Single-Particle Cryo-Electron Microscopy and Hydrogen/ Deuterium Exchange Mass Spectrometry to Elucidate the Structure and Dynamics of G-Protein Coupled Receptors, Presented by Paola C., NovAliX

B40: Screen, Scale, Capture, Characterize: Rapid Functional Protein Production and Characterization of Drug-Target Interactions, Presented by Aujan M., Nuclera

B41: Cell Free Expression of E3 Ubiquitin Ligases to Accelerate Target Protein Degradation Studies, Presented by Yvonne T., Nuclera

B42: Integration of Untargeted Metabolomics with Targeted Profiling of Inflammatory Proteins to Define the Metabolic Fingerprint of Inflammation in COVID-19, Presented by Arnold S., PanomeBio

B43: A Mechanical Delivery Platform Enabling Intracellular Delivery of Impermeable Small Molecules, Peptides, and Probes for Enhanced Drug Discovery, Presented by Jacquelyn H., Portal Biotechnologies

B44: A Bioluminescent, Homogeneous Assay for Monitoring GPCR-Mediated cAMP Modulation and Adenylate Cyclase Activity, Presented by Kristin H., Promega Corporation

B45: Exploring the Landscape of PARP and PARG inhibitor Selectivity in Live Cells Using NanoBRET™ Target Engagement Assays, Presented by Alissa K., Promega Corporation

B46: HiBiT Protein Tagging System to Study Protein Interactions at Endogenous Levels, Presented by Amy L., Promega Corporation

B47: Advancing Therapeutic Strategies for Obesity: Innovative Bioluminescent Assays for Monitoring GPCR Dynamics, Presented by Megan L., Promega Corporation

B48: Novel Drug Discovery Platform Based on Quantum Computing and AI, Presented by Sungmin L., Qunova Computing, Inc.

B49: Quantum Computing Approaches for Enhancing Molecule Discovery in Qunova Computing, Presented by Jaehong S., Qunova Computing, Inc.

B50: Filling the Gap in LogP and pKa Evaluation for Saturated Fluorine-Containing Derivatives with Machine Learning, Presented by Oleksandr G., Lviv Polytechnic National University

B51: An Integrated Text-Mining and Network Modeling Approach for Target Identification Validated in MASH-Induced Liver Fibrosis, Presented by Jennifer MV., TNO Nutrition and Food Research

B52: TargetTri: Automated Classification of Target Modulation and Associated Effects in PubMed Using BERT-Based Models, Presented by Jennifer MV., TNO Nutrition and Food Research

B53: Developing Robust Cell-Based Assays to Evaluate Efficacy of MYC-PNUTS Inhibitors, Presented by Melissa S., University Health Network

B54: DEL Screening Methods to Find High-Quality and Structurally Diverse Novel Hits as Starting Points for New GPCR Modulators, Presented by Anthony K., X-Chem, Inc.

B55: Phospho-Ubiquitin: A Biomarker for Neurodegeneration, Presented by Tauseef B., Progenra, Inc.

B56: Benchmarking OpenMM on 25 Different Consumer GPUs at 95% Less Cost, Presented by Bob M., Salad Technologies